Bristol-Myers Squibb Co. BMY
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Bristol-Myers Squibb Co. (BMY) Business Model and Operations Summary
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Key Insights
Bristol-Myers Squibb Co. (BMY) Core Market Data and Business Metrics
Latest Closing Price
$59.55Market Cap
$121.16 BillionPrice-Earnings Ratio
-13.50Total Outstanding Shares
2.03 Billion SharesTotal Employees
34,100Dividend
$0.62 Per Share QuarterlyIPO Date
June 23, 1952SIC Description
Pharmaceutical PreparationsPrimary Exchange
New York Stock ExchangeHeadquarters
Route 206 And Province Line Road, Princeton, NJ, 08543
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Financing Activities, Continuing | $5.13 Billion |
| Net Cash Flow From Operating Activities, Continuing | $15.19 Billion |
| Net Cash Flow From Investing Activities | $-21.35 Billion |
| Net Cash Flow From Operating Activities | $15.19 Billion |
| Net Cash Flow From Investing Activities, Continuing | $-21.35 Billion |
| Net Cash Flow From Financing Activities | $5.13 Billion |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Costs And Expenses | $56.68 Billion |
| Revenues | $48.30 Billion |
| Income/Loss From Equity Method Investments | $44 Million |
| Income Tax Expense/Benefit | $554 Million |
| Net Income/Loss Available To Common Stockholders, Basic | $-8.95 Billion |
| Income Tax Expense/Benefit, Current | $2.64 Billion |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Other Comprehensive Income/Loss | $308 Million |
| Comprehensive Income/Loss Attributable To Parent | $-8.64 Billion |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $15 Million |
| Comprehensive Income/Loss | $-8.63 Billion |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Noncurrent Assets | $62.82 Billion |
| Fixed Assets | $7.14 Billion |
| Long-term Debt | $49.43 Billion |
| Current Assets | $29.78 Billion |
| Wages | $1.69 Billion |
| Equity | $16.39 Billion |
Historical Dividends
Current dividend: $0.62 Per Share Quarterly
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| Mar 3, 2025 | May 1, 2025 | Apr 4, 2025 | $0.62 | Quarterly |
| Dec 11, 2024 | Feb 3, 2025 | Jan 3, 2025 | $0.62 | Quarterly |
| Sep 10, 2024 | Nov 1, 2024 | Oct 4, 2024 | $0.6 | Quarterly |
| Jun 18, 2024 | Aug 1, 2024 | Jul 5, 2024 | $0.6 | Quarterly |
| Mar 1, 2024 | May 1, 2024 | Apr 5, 2024 | $0.6 | Quarterly |
| Dec 6, 2023 | Feb 1, 2024 | Jan 5, 2024 | $0.6 | Quarterly |